Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice

Circulation

Volumn 110, Issue 13, 2004, Pages 1819-1825

  Garnier, Anne ^a   Bendall, Jennifer K ^a   Fuchs, Sebastien ^b   Escoubet, Brigitte ^c   Rochais, Francesca ^a   Hoerter, Jacqueline ^a   Nehme, Johnny ^a   Ambroisine, Marie Lory ^a   De Angelis, Noeleen ^e   Morineau, Gilles ^d   D'Estienne, Pauline ^a   Fischmeister, Rodolphe ^a   Heymes, Christophe ^a   Pinet, Florence ^f   Delcayre, Claude ^a,g  

^a INSERM   (France)

^b l'alimentation et l'Environnement   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^f INSTITUT PASTEUR DE LILLE   (France)

^g HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Aldosterone; Genes; Heart diseases; Hormones

Indexed keywords

ALDOSTERONE; ALDOSTERONE SYNTHASE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; COLLAGEN; MESSENGER RNA; MYOSIN HEAVY CHAIN;

ADAPTATION; ALDOSTERONE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; ECHOCARDIOGRAPHY; GENE TARGETING; HEART FUNCTION; HEART MUSCLE FIBROSIS; HEART PERFUSION; HORMONE SYNTHESIS; ISOLATED HEART; MALE; MOUSE; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RECEPTOR BINDING; TRANSGENIC MOUSE; VASODILATATION; WILD TYPE;

EID: 20844459494     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000142858.44680.27     Document Type: Article

References (34)

1. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717.
2. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
3. Delcayre C, Swynghedauw B. Molecular mechanisms of myocardial remodeling: the role of aldosterone. J Mol Cell Cardiol. 2002;34:1577-1584.
4. Brilla C, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol. 1993;125:563-575.
5. Robert V, Silvestre JS, Charlemagne D, et al. Biological determinants of aldosterone-induced cardiac fibrosis in rat. Hypertension. 1995;26:971-978.
6. Rocha R, Rudolph AE, Frierdich GE, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol. 2002;283:H1802-H1810.
7. Sun Y, Zhang J, Lu L, et al. Aldosterone-induced inflammation in the rat heart. Am J Pathol. 2002;161:1773-1781.
8. Gerling IC, Sun Y, Ahokas RA, et al. Aldosteronism: an immunostimulatory state precedes proinflammatory/fibrogenic cardiac phenotype. Am J Physiol. 2003;285:H813-H821.
9. Silvestre JS, Robert V, Heymes C, et al. Myocardial production of aldosterone and corticosterone in the rat: physiological regulation. J Biol Chem. 1998;273:4883-4891.
10. Silvestre JS, Heymes C, Cubénïssa A, et al. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II blockade and role in cardiac fibrosis. Circulation. 1999;99:2694-2701.
11. Casal AJ, Silvestre JS, Delcayre C, et al. Expression and modulation of the steroidogenic acute regulatory (StAR) protein mRNA in rat cardiocytes and after myocardial infarction. Endocrinology. 2003;144:1861-1868.
12. Young MJ, Clyne CD, Cole TJ, et al. Cardiac steroidogenesis in the normal and failing heart. J Clin Endocrinol Metab. 2001;86:5121-5126.
13. Yoshimura M, Nakamura S, Ito T, et al. Expression of aldosterone synthase gene in failing human heart: quantitative analysis using modified real-time polymerase chain reaction. J Clin Endocrinol Metab. 2002;87:3936-3940.
14. Tsybouleva N, Zhang L, Chen S, et al. Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation. 2004;109:1284-1291.
15. Mizuno Y, Yoshimura M, Yasue H, et al. Aldosterone production is activated in failing ventricle in humans. Circulation. 2001;103:72-77.
16. Subramaniam A, Jones WK, Gulick J, et al. Tissue-specific regulation of the alpha-myosin heavy chain gene promoter in transgenic mice. J Biol Chem. 1991;266:24613-24620.
17. Oliviero P, Chassagne C, Kolar F, et al. Effect of pressure overload on angiotensin receptor expression in the rat heart during early post-natal life. J Mol Cell Cardiol. 2000;32:1631-1645.
18. Cherradi N, Brandenburger Y, Rossier MF, et al. Atrial natriuretic peptide inhibits calcium-induced steroidogenic acute regulatory protein gene transcription in adrenal glomerulosa cells. Mol Endocrinol. 1998;12:962-972.
19. Beggah AT, Escoubet B, Puttini S, et al. Reversible cardiac fibrosis and heart failure induced by conditional expression of an antisense mRNA of the mineralocorticoid receptor in cardiomyocytes. Proc Natl Acad Sci USA. 2002;99:7160-7165.
20. 2+ current in transgenic mice with a cardiac-directed expression of the human adenylyl cyclase type 8 (AC8). FASEB J, 2002;16:1636-1638.
21. Bendall JK, Heymes C, Wright TJ, et al. Strain-dependent variation in vascular responses to nitric oxide in the isolated murine heart. J Mol Cell Cardiol. 2002;34:1325-1333.
22. 2+/calmodulin-dependent protein kinases II in human atrial myocytes. Circ Res. 1999;85:810-819.
23. White PC. Aldosterone: direct effects on and production by the heart. J Clin Endocrinol Metab. 2003;88:2376-2383.
24. Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001;345:1689-1697.
25. 2+ current in adult rat cardiomyocytes. Circ Res. 1999;85:1139-1145.
26. + current density in rat ventricular myocytes. J Physiol. 2001;537:151-160.
27. Struthers AD, MacDonald TM. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res. 2004;61:663-670.
28. Farquharson CAJ, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000;101:594-597.
29. Bauersachs J, Heck M, Fraccarollo D, et al. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol. 2002;39:351-358.
30. Virdis A, Neves MF, Amiri F, et al. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension. 2002;40:504-510.
31. Rajagopalan S, Duquaine D, King S, et al. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation. 2002;105:2212-2216.
32. Lariviere R, Deng LY, Day R, et al. Increased endothelin-I gene expression in the endothelium of coronary arteries and endocardium in the DOCA-salt hypertensive rat. J Mol Cell Cardiol. 1995;27:2123-2131.
33. Robert V, Thiem NV, Cheav SL, et al. Increased cardiac collagens (I) and (III) mRNAs in aldosterone-salt hypertension. Hypertension. 1994;24:30-36.
34. Young MJ, Moussa L, Dilley R, et al. Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: effects of II beta-hydroxysteroid dehydrogenase inactivation. Endocrinology. 2003;144:1121-1125.